Yang, C., Tsai, M., Hung, J., Liu, T., Chou, S., Lee, J., . . . Chong, I. (2016). Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment. Onco Targets Ther.
Chicago Stili AlıntıYang, Chih-Jen, et al. "Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-based Chemotherapy After Developing Resistance to the First-line Gefitinib Treatment." Onco Targets Ther 2016.
MLA AlıntıYang, Chih-Jen, et al. "Pemetrexed Had Significantly Better Clinical Efficacy in Patients With Stage IV Lung Adenocarcinoma With Susceptible EGFR Mutations Receiving Platinum-based Chemotherapy After Developing Resistance to the First-line Gefitinib Treatment." Onco Targets Ther 2016.